Flow cytometric evaluation of lymphoid and myeloid populations in primary cux/CDPΔHD/ΔHD mice, crossed to IgH “knock-in” and TCRβ transgenics
| Populations* . | CT . | ΔHD . | IgH knock-in CT1-153 . | IgH knock-in ΔHD1-153 . | TCR-β TG CT1-153 . | TCR-β TG ΔHD1-153 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | |
| Bone marrow | N/A | (14.2 ± 3.7) | N/A | (16.7 ± 3.1) | N/A | (21.1 ± 2.4) | N/A | (18.7 ± 0.7) | ND | ND | ND | ND |
| B220+ | 37.8 ± 6.5 | (5.0 ± 1.2) | 15.1 ± 7.21-155 | (2.6 ± 1.3)1-155 | 37.5 ± 3.1 | (8.0 ± 1.5) | 13.7 ± 5.31-154 | (2.5 ± 0.9)1-154 | ND | ND | ND | ND |
| B220+c-Kit+ | 5.7 ± 1.1 | (0.8 ± 0.2) | 3.4 ± 0.91-155 | (0.6 ± 0.1) | 2.4 ± 0.4 | (0.5 ± 0.1) | 2.4 ± 0.8 | (0.4 ± 0.1) | ND | ND | ND | ND |
| B220+CD25+ | 12.8 ± 3.0 | (1.9 ± 0.6) | 3.7 ± 2.01-155 | (0.6 ± 0.3)1-155 | 15.7 ± 3.4 | (3.4 ± 1.0) | 3.9 ± 3.01-154 | (0.7 ± 0.5)1-154 | ND | ND | ND | ND |
| B220+IgM+ | 12.7 ± 2.6 | (1.6 ± 0.4) | 7.8 ± 3.11-155 | (1.2 ± 0.5) | 9.1 ± 2.0 | (1.9 ± 0.4) | 3.8 ± 1.51-154 | (0.7 ± 0.3)1-154 | ND | ND | ND | ND |
| Mac-1+B220− | 28.3 ± 4.6 | (4.2 ± 1.2) | 55.8 ± 7.21-155 | (9.2 ± 2.3)1-155 | 38.8 ± 1.0 | (8.2 ± 1.1) | 58.6 ± 8.61-154 | (11.0 ± 1.9) | ND | ND | ND | ND |
| Spleen | N/A | (109 ± 31) | N/A | (75 ± 63) | N/A | (70.0 ± 24.4) | N/A | (82.1 ± 38.2) | N/A | ND | N/A | ND |
| B220+ | 59.2 ± 7.3 | (64.2 ± 6.2) | 47.6 ± 8.2 | (46.4 ± 20.7) | 35.2 ± 5.8 | (23.2 ± 3.9) | 20.6 ± 3.71-154 | (16.6 ± 7.8) | ND | ND | ND | ND |
| Mac-1+B220− | 5.3 ± 0.7 | (6.0 ± 1.7) | 18.6 ± 6.41-154 | (20.4 ± 14.8) | 10.4 ± 3.1 | (6.6 ± 0.9) | 20.5 ± 10.1 | (13.1 ± 4.8) | ND | ND | ND | ND |
| CD4+ | 6.9 ± 0.9 | (6.8 ± 1.6) | 12.5 ± 4.31-154 | (9.0 ± 4.4) | ND | ND | ND | ND | ND | ND | ND | ND |
| CD8+ | 2.7 ± 0.6 | (2.7 ± 0.5) | 4.1 ± 1.4 | (3.2 ± 1.8) | ND | ND | ND | ND | ND | ND | ND | ND |
| Thymus | N/A | (202 ± 97) | N/A | (43 ± 44)1-155 | ND | ND | ND | ND | N/A | (140 ± 30.8) | N/A | (10 ± 16)1-155 |
| lin−CD4−CD8− | 2.0 ± 0.6 | (3.9 ± 1.7) | 3.0 ± 2.8 | (0.8 ± 0.4)1-154 | ND | ND | ND | ND | 5.8 ± 2.2 | (8.2 ± 3.7) | 9.0 ± 6.2 | (0.5 ± 0.5)1-155 |
| CD4+CD8+ | 83.8 ± 2.8 | (171 ± 84) | 61.8 ± 28.71-154 | (37 ± 38)1-155 | ND | ND | ND | ND | 82.8 ± 5.2 | (113 ± 17.8) | 54.2 ± 33.8 | (6.1 ± 12)1-155 |
| CD4+CD8− | 9.9 ± 1.7 | (19.6 ± 9.3) | 24.4 ± 181-155 | (13.4 ± 22) | ND | ND | ND | ND | 8.7 ± 3.5 | (13.6 ± 6.9) | 29.8 ± 23.8 | (2.8 ± 3.4)1-154 |
| CD4−CD8+ | 3.94 ± 1.2 | (7.7 ± 3.7) | 8.3 ± 8.9 | (1.6 ± 1.0)1-155 | ND | ND | ND | ND | 5.5 ± 3.4 | (8.4 ± 6.6) | 11.1 ± 9.3 | (0.9 ± 0.9)1-154 |
| CD3intCD25int | 2.4 ± 0.9 | (4.8 ± 3.3) | 16.2 ± 5.51-155 | (9.5 ± 11.3) | ND | ND | ND | ND | ND | ND | ND | ND |
| Populations* . | CT . | ΔHD . | IgH knock-in CT1-153 . | IgH knock-in ΔHD1-153 . | TCR-β TG CT1-153 . | TCR-β TG ΔHD1-153 . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | % cells† . | No. cells × 105‡ . | |
| Bone marrow | N/A | (14.2 ± 3.7) | N/A | (16.7 ± 3.1) | N/A | (21.1 ± 2.4) | N/A | (18.7 ± 0.7) | ND | ND | ND | ND |
| B220+ | 37.8 ± 6.5 | (5.0 ± 1.2) | 15.1 ± 7.21-155 | (2.6 ± 1.3)1-155 | 37.5 ± 3.1 | (8.0 ± 1.5) | 13.7 ± 5.31-154 | (2.5 ± 0.9)1-154 | ND | ND | ND | ND |
| B220+c-Kit+ | 5.7 ± 1.1 | (0.8 ± 0.2) | 3.4 ± 0.91-155 | (0.6 ± 0.1) | 2.4 ± 0.4 | (0.5 ± 0.1) | 2.4 ± 0.8 | (0.4 ± 0.1) | ND | ND | ND | ND |
| B220+CD25+ | 12.8 ± 3.0 | (1.9 ± 0.6) | 3.7 ± 2.01-155 | (0.6 ± 0.3)1-155 | 15.7 ± 3.4 | (3.4 ± 1.0) | 3.9 ± 3.01-154 | (0.7 ± 0.5)1-154 | ND | ND | ND | ND |
| B220+IgM+ | 12.7 ± 2.6 | (1.6 ± 0.4) | 7.8 ± 3.11-155 | (1.2 ± 0.5) | 9.1 ± 2.0 | (1.9 ± 0.4) | 3.8 ± 1.51-154 | (0.7 ± 0.3)1-154 | ND | ND | ND | ND |
| Mac-1+B220− | 28.3 ± 4.6 | (4.2 ± 1.2) | 55.8 ± 7.21-155 | (9.2 ± 2.3)1-155 | 38.8 ± 1.0 | (8.2 ± 1.1) | 58.6 ± 8.61-154 | (11.0 ± 1.9) | ND | ND | ND | ND |
| Spleen | N/A | (109 ± 31) | N/A | (75 ± 63) | N/A | (70.0 ± 24.4) | N/A | (82.1 ± 38.2) | N/A | ND | N/A | ND |
| B220+ | 59.2 ± 7.3 | (64.2 ± 6.2) | 47.6 ± 8.2 | (46.4 ± 20.7) | 35.2 ± 5.8 | (23.2 ± 3.9) | 20.6 ± 3.71-154 | (16.6 ± 7.8) | ND | ND | ND | ND |
| Mac-1+B220− | 5.3 ± 0.7 | (6.0 ± 1.7) | 18.6 ± 6.41-154 | (20.4 ± 14.8) | 10.4 ± 3.1 | (6.6 ± 0.9) | 20.5 ± 10.1 | (13.1 ± 4.8) | ND | ND | ND | ND |
| CD4+ | 6.9 ± 0.9 | (6.8 ± 1.6) | 12.5 ± 4.31-154 | (9.0 ± 4.4) | ND | ND | ND | ND | ND | ND | ND | ND |
| CD8+ | 2.7 ± 0.6 | (2.7 ± 0.5) | 4.1 ± 1.4 | (3.2 ± 1.8) | ND | ND | ND | ND | ND | ND | ND | ND |
| Thymus | N/A | (202 ± 97) | N/A | (43 ± 44)1-155 | ND | ND | ND | ND | N/A | (140 ± 30.8) | N/A | (10 ± 16)1-155 |
| lin−CD4−CD8− | 2.0 ± 0.6 | (3.9 ± 1.7) | 3.0 ± 2.8 | (0.8 ± 0.4)1-154 | ND | ND | ND | ND | 5.8 ± 2.2 | (8.2 ± 3.7) | 9.0 ± 6.2 | (0.5 ± 0.5)1-155 |
| CD4+CD8+ | 83.8 ± 2.8 | (171 ± 84) | 61.8 ± 28.71-154 | (37 ± 38)1-155 | ND | ND | ND | ND | 82.8 ± 5.2 | (113 ± 17.8) | 54.2 ± 33.8 | (6.1 ± 12)1-155 |
| CD4+CD8− | 9.9 ± 1.7 | (19.6 ± 9.3) | 24.4 ± 181-155 | (13.4 ± 22) | ND | ND | ND | ND | 8.7 ± 3.5 | (13.6 ± 6.9) | 29.8 ± 23.8 | (2.8 ± 3.4)1-154 |
| CD4−CD8+ | 3.94 ± 1.2 | (7.7 ± 3.7) | 8.3 ± 8.9 | (1.6 ± 1.0)1-155 | ND | ND | ND | ND | 5.5 ± 3.4 | (8.4 ± 6.6) | 11.1 ± 9.3 | (0.9 ± 0.9)1-154 |
| CD3intCD25int | 2.4 ± 0.9 | (4.8 ± 3.3) | 16.2 ± 5.51-155 | (9.5 ± 11.3) | ND | ND | ND | ND | ND | ND | ND | ND |
N/A indicates not applicable; ND, no data.
B and T lymphoid and myeloid cell populations in cux/CDPΔHD/ΔHD (ΔHD) and control wild-type/heterozygous littermate (CT) hematopoietic tissues were analyzed by flow cytometry using lineage- and stage-specific antibodies.
Data presented are the percentages of cells staining positive for specific surface antigens within the population analyzed (viable gate for bone marrow and spleen; viable lymphoid gate for thymus).
Population cell numbers (× 105), shown in parentheses, are normalized for body weight (spleen and thymus) and additionally per femur (bone marrow).
Population percentages and cell numbers are also shown for cux/CDPΔHD/ΔHD and control mice crossed to the IgH “knock-in” (Ig) and TCRβ (TCR) transgenic lines.
P < .005.
P < .05.